Company news
Atrium Therapeutics, Inc. news in 2021
Atrium Therapeutics, Inc.'s news releases, calls and decks from 2021, newest first.
Avidity Biosciences Highlights FSHD Program at Virtual Investor and Analyst Event
December 8, 2021
Avidity Biosciences Reports Third Quarter 2021 Financial Results and Recent Highlights
November 8, 2021
Avidity Announces First Person Dosed with an Antibody Oligonucleotide Conjugate (AOC™)
November 3, 2021
FDA Grants Fast Track Designation to AOC 1001 for the Treatment of Myotonic Dystrophy Type 1
October 17, 2021
Avidity Biosciences Announces Changes to its Board of Directors
August 24, 2021
European Medicines Agency (EMA) Grants Orphan Designation for AOC 1001
August 23, 2021
Avidity Biosciences Enters Into Collaboration with FSHD Clinical Trial Network to Support Development of Biomarkers for Future Clinical Trial Use
August 15, 2021
Avidity Biosciences Reports Second Quarter 2021 Financial Results and Recent Highlights
August 8, 2021
Avidity Biosciences Receives IND Clearance from FDA to Proceed with the Phase 1/2 MARINA™ Trial of AOC 1001 in Adults with Myotonic Dystrophy (DM1)
August 1, 2021
Avidity Biosciences Announces Updates on the Pipeline and Platform at Virtual Investor and Analyst Event
May 18, 2021
Avidity Biosciences Reports First Quarter 2021 Financial Results and Recent Highlights
May 11, 2021
Avidity Biosciences to Host Virtual Investor and Analyst Event on May 19, 2021
May 2, 2021
Avidity Biosciences to Present Oral Presentation on AOC 1001 for DM1 at American Academy of Neurology (AAN) 2021 Virtual Annual Meeting
April 15, 2021
Avidity Biosciences Reports Fourth Quarter and Year-End 2020 Financial Results and Recent Highlights
March 14, 2021
Avidity Biosciences to Present at the 10th Annual SVB Leerink Global Healthcare Conference
February 16, 2021
Avidity Biosciences Appoints W. Michael Flanagan, Ph.D. as Chief Technical Officer
January 20, 2021
Avidity Biosciences Announces 2021 Pipeline Updates and Research Collaboration with MyoKardia
January 7, 2021